HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
nasaruplase
a native single-chain urokinase-type plasminogen activator; a proenzyme converted only at the thrombus surface
Networked:
3
relevant articles (
1
outcomes,
0
trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Enzymes and Coenzymes: 1
Enzymes: 152586
Hydrolases: 2166
Peptide Hydrolases: 23957
Serine Proteases: 3726
Serine Endopeptidases: 11
Urokinase-Type Plasminogen Activator: 5828
nasaruplase: 3
Endopeptidases: 633
Serine Endopeptidases: 11
Urokinase-Type Plasminogen Activator: 5828
nasaruplase: 3
Amino Acids, Peptides, and Proteins: 1
Proteins: 484843
Blood Proteins: 12459
Blood Coagulation Factors: 5376
Plasminogen Activators: 5174
Urokinase-Type Plasminogen Activator: 5828
nasaruplase: 3
Related Diseases
1.
Myocardial Infarction
01/01/1995 - "
An examination was made of the coronary thrombolytic effects of nasaruplase in a canine model of acute myocardial infarction.
"
01/01/1995 - "
Low incidence of hemorrhagic infarction following coronary reperfusion with nasaruplase in a canine model of acute myocardial infarction.
"
02/01/1993 - "
These results indicate that coronary thrombolytic therapy with intravenous administration of nasaruplase is useful for the treatment of acute myocardial infarction.
"
02/01/1993 - "
The thrombolytic effects and changes in left ventricular function after intravenous administration of nasaruplase were examined in a canine thrombus model of acute myocardial infarction.
"
02/01/1993 - "
[Effects of intravenous administration of nasaruplase, a plasminogen pro-activator, on left ventricular function and systemic hemodynamics in a canine model of acute myocardial infarction].
"
2.
Infarction (Infarctions)
01/01/1995 - "
Hemorrhagic infarction occurred in 2 of 14 animals in the nasaruplase group and in 9 of 19 animals in the rt-PA group.
"
01/01/1995 - "
Low incidence of hemorrhagic infarction following coronary reperfusion with nasaruplase in a canine model of acute myocardial infarction.
"
01/01/1995 - "
It is concluded that nasaruplase is a potent thrombolytic agent which preserves left ventricular function with a lesser rate of hemorrhagic infarction than rt-PA.
"
02/01/1993 - "
Nasaruplase markedly reduced infarct size as well as cardiac hypertrophy following coronary arterial occlusion, demonstrating suppression of the development of ischemic myocardial damage.
"
3.
Thrombosis (Thrombus)
02/01/1993 - "
The thrombolytic effects and changes in left ventricular function after intravenous administration of nasaruplase were examined in a canine thrombus model of acute myocardial infarction.
"
4.
Retinal Vein Occlusion
01/01/1996 - "
[Medical treatment for experimental retinal vein occlusion--thrombolytic effect of nasaruplase].
"
01/01/1996 - "
The anti-thrombolytic effect of urokinase (UK), nasaruplase, and argatroban was studied using an experimental rabbit model of retinal vein occlusion (RVO).
"
5.
Cardiomegaly (Heart Hypertrophy)
02/01/1993 - "
Nasaruplase markedly reduced infarct size as well as cardiac hypertrophy following coronary arterial occlusion, demonstrating suppression of the development of ischemic myocardial damage.
"
Related Drugs and Biologics
1.
Urokinase-Type Plasminogen Activator (Urokinase)
2.
Plasminogen
3.
Fibrinolytic Agents (Antithrombotic Agents)
4.
Fibrinogen (Factor I)
5.
argatroban (MPQA)
Related Therapies and Procedures
1.
Intravenous Administration
2.
Thrombolytic Therapy